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Abstract 
PRRSV is the etiological agent of one of the most important swine diseases with a significant economic burden 
worldwide and limitations in vaccinology. Exosomes are 30–100 nm vesicles of endocytic origin. Remarkably, immu‑
nizations with exosomes containing antigens from tumors or pathogens are capable of eliciting protective immune 
responses, albeit variably, in cancer and infectious diseases. Here we describe the isolation, molecular composition 
and immunogenicity of serum‑derived exosomes from naïve animals, from PRRSV viremic animals and from animals 
previously PRRSV infected but already free of viruses (non viremic). Exosomes were isolated through size exclusion 
chromatography and characterized by different methodologies. Exosome‑enriched fractions from naïve and natural 
infected animals contained classical tetraspanin exosomal markers (CD63 and CD81) and high concentrations of 
particles in the size‑range of exosomes as detected by nanoparticle tracking analysis and cryo‑TEM. NanoLC‑MS/MS 
was used to identify viral antigens associated to exosomes. PRRSV‑proteins were detected in serum samples from 
only viremic animals and from animals previously infected already free of viruses (non‑viremic), but not in controls. 
Moreover, immune sera from pigs previously exposed to PRRSV specifically reacted against exosomes purified from 
non‑viremic pig sera in a dose‑dependent manner, a reactivity not detected when naïve sera was used in the assay. To 
facilitate future studies, a scaling‑up process was implemented. To the best of our knowledge, this is the first molecu‑
lar characterization of serum‑derived exosomes from naïve pigs and pigs actively or previously infected with PRRSV. 
The presence of antigenic viral proteins in serum‑derived exosomes free of virus, suggest their use as a novel vaccine 
approach against PRRSV.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Porcine reproductive and respiratory virus (PRRSV) is 
the etiological agent of one of the most important swine 
diseases with a significant economic burden worldwide. 
Only in the US, it is estimated that $560 million yearly 
losses are directly related to this disease [1]. Current 
vaccines against PRRSV have focused on methods using 
modified live or attenuated virus [2], peptides [3], vec-
tored vaccines [4], inactivated virus and subunit vaccines 
[5–7]. Available vaccines, however, have limitations such 
as little protective immunity [8], possible reversion to 
virulence [9], and incapability of eliciting long lasting and 
heterologous protection among European and Ameri-
can genotypes [10]. In addition, PRRSV strains have high 
antigenic variability and genetic polymorphisms [11, 12] 
and the highest mutation rate of RNA viruses [5]. All 
together, these limitations indicate that new alternatives 
to conventional vaccines are desperately needed aiming 
to control and eventually eradicating PRRSV.
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Exosomes are 30–100  nm vesicles of endocytic origin 
originally described as a “garbage-disposable” mecha-
nism of reticulocytes in their terminal differentiation to 
erythrocytes [13, 14]. This cellular origin and function 
were shown not to be unique as 10  years later, B-cells 
were also described to secrete exosomes with antigen 
presentation capacity and with the ability of generat-
ing specific T-cell responses [15]. Since these seminal 
observations, exosomes have been shown to be secreted 
by all immune cells and explored as novel vaccination 
approaches [16]. In fact, proof-of-principle Phase I clini-
cal trials using dendritic cell-derived exosomes coupled 
to tumor-associated antigens have shown their safety and 
immunogenicity in cancer and Phase II trials are pres-
ently being conducted [17]. Of interest, antigens from 
infectious diseases associated with exosomes also dem-
onstrated their capacity for eliciting specific and pro-
tective immune responses in preclinical mouse models 
[18–20]. For instance, vaccination with extracellular vesi-
cles and exosomes can induce a strong immune response 
and increase survival in Mycobacterium tuberculosis, 
Eimeria tenella, Toxoplasma gondii [18, 19] and full pro-
tection against a lethal challenge in Plasmodium yoelii 
experimental infections [21]. Moreover, outer membrane 
vesicles (OMVs) derived from Bordetella pertussis used 
as vaccine in mice ameliorated infection following chal-
lenge with several strains [20]. For virus, exosomes play 
an important role not only involved in pathogenesis and 
virus spreading [22] but also in cell communication and 
protection against infection [23]. All together, these data 
strongly suggest the value of exosomes as a new vacci-
nation approach in human health. Yet, no reports have 
shown their potential value for vaccination in animal 
health.
In this work, we describe the isolation and molecular 
composition of serum-derived exosomes obtained from 
naïve pigs, from viremic animals and from non-viremic 
animals previously infected with PRRSV. Our results 
unequivocally identified viral antigens associated to 
exosomes in viremic and non-viremic pigs. Moreover, 
viral proteins contained in serum-derived exosomes from 
non-viremic animals exhibit antigenic potential as judged 
by ELISA assays. A scaling-up protocol for obtain-
ing serum-derived exosomes was also developed. Thus, 
opening the possibility of exploring these non-viremic 
nanovesicles as a novel vaccination approach against 
PRRSV.
Materials and methods
Samples
Sera were obtained from large white X Landrace pigs of 
approximately seventeen weeks of age that had suffered 
a PRRSV natural outbreak in two conventional farms 
and from animals of one PRRSV negative farm (naive 
pigs). The two PRRSV positive farms belong to the same 
integration company but from different sow origin. The 
PRRSV negative farm pertains to a different integration 
Company; thus, avoiding any confounding with sam-
ples. Viral as well as serological status of animals against 
PRRSV antigens were analyzed, respectively, by RT-PCR 
TaqMan® NA/EU PRRSV Reagents (Applied Biosystems) 
and IDEXX PRRS X3 Antibody Test (IDEXX). An inde-
pendent diagnostics laboratory for porcine diseases in 
Lleida [24] confirmed these analyses following their own 
standard operational procedures.
Sera from all animals were classified as non-viremic 
(NV, PRRSV negative by RT-PCR) or viremic (V, PRRSV 
positive by RT-PCR), being both groups serologically 
positive to PRRSV using an IDEXX PRRS X3 Antibody 
Test. On the other hand, sera from naive control ani-
mals (CN) were PRRSV negative and free from antibod-
ies against PRRSV. Details of sera used in this study are 
included in Additional file  1. All studies were approved 
by the ethical committee of the University of Lleida, 
Spain, and performed under their guidelines for animal 
care (DAAM7684).
Exosome isolation: size‑exclusion chromatography
Isolation of serum-derived exosomes by size exclusion 
chromatography (SEC) were performed as previously 
described [25]. Briefly, Sepharose CL-2B (Sigma-Aldrich, 
St. Louis, MO, USA) was packed in 10 mL syringes to a 
final volume of 10 mL and equilibrated with PBS-Citrate 
0.32% (w/v). Frozen serum samples were thawed on ice, 
centrifuged at 500×g for 10 min at room temperature to 
remove cellular debris, and 2  mL aliquots were applied 
to each column. Collection of 20 fractions of 0.5  mL 
each started immediately using PBS-citrate as the elu-
tion buffer. Protein content of each fraction was analyzed 
using Bradford protein quantification assay according to 
manufacturer’s instructions (Bradford reagent, Sigma-
Aldrich). To determine protein profiles, samples were 
loaded into 10% polyacrylamide BIORAD precast gels, 
separated at 120 V for 45 min and stained using Silver-
QuestTM Staining kit (Invitrogen).
Flow cytometry analysis of molecular markers associated 
with extracellular vesicles
A bead-based assay for detection of two classical exosome 
markers, CD63 and CD81 was used to phenotypically 
identify SEC fractions containing exosomes [26]. Briefly, 
exosomes were coupled with Aldehyde/Sulfate Latex 
Beads, 4% w/v, 4 µm (Invitrogen) and then blocked with 
PBS 1X/BSA 0.1% (Sigma-Aldrich) /NaN3 0.01% (Sigma-
Aldrich). Fractions were incubated in microtest conical 
bottom 96-well plates for 30 min at 4 °C with anti-CD63 
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and anti-CD81 antibodies (culture supernatant monoclo-
nal antibodies) at 1:10 dilution. After washing, a 1/100 
dilution of secondary antibody FITC (Southern Bio-
tech) was incubated for 30 min at 4 °C. After removal of 
unbound secondary antibodies by centrifugation, beads 
were suspended in PBS and analyzed by flow cytom-
etry using aBD FACSVerse (BD Biosciences) equipment. 
Median Fluorescence Intensity (MFI) and beads count 
data were obtained by FlowJo analysis Software of every 
sample-reading file.
Nanoparticle tracking analysis (NTA)
Diameter size and concentration of vesicle population 
was determined using NanoSight LM10 equipment (Mal-
vern). Fractions were evaluated using different dilutions 
in sterile-filtered PBS 1X (1/10 to 1/50) and the following 
parameters: camera at 30 frames per second (FPS), cam-
era level at 16, temperature between 21–25 °C and video 
recording time 60 s in order to estimate the concentration 
and size distribution of vesicle population through light 
scattering and Brownian motion. Nanosight NTA Soft-
ware analyzed raw data videos by triplicate and results 
were obtained in PDF datasheet with all selected values 
(Mean size, Median size, Mode size and concentration).
Cryo‑electron microscopy (Cryo‑TEM)
Ten microliter aliquots from individual SEC fractions 
containing exosomes were directly laid on Formvar-
Carbon EM grids and frozen in ethanol. Samples were 
analyzed on a Jeol JEM 2011 transmission electron 
microscope at an accelerating voltage of 200  kV. Sam-
ples and the 626 Gatan cryoholder were maintained at 
−182  °C during the whole process. To minimize elec-
tron bean radiation, images were recorded on a Gatan 
Ultrascan cooled CCD camera under low electron dose 
conditions. Vesicle size was determined using the ImageJ 
software (NIH) and setting calibration was performed 
pixels/nanometer.
Mass spectrometry
Liquid Chromatography (nanoLCULTRA-EKSIGENT) 
followed by mass spectrometry (nanoLC-MS/MS) was 
performed on a LTQ Orbitrap Velos (Thermo Fisher). 
Briefly, samples were reduced with 10 mM DTT (Dithi-
othreitol), alkylated with 55 mM iodoacetamide and pre-
cipitated by 10% TCA. After washing with acetone, 2 μL 
of 8  M urea were added and samples brought to a final 
concentration of 1.6 M urea. One microgram of trypsin 
(Sus scrofa) was added and digestions were carried over-
night at 37 °C. The reaction was stopped with 1% formic 
acid. The amount of sample submitted to mass spectrom-
etry analyses was based on nanoparticle tracking analy-
sis (see below) and ranged from 9.8 ×  107 to 3.9 ×  108 
particles/mL among all samples analyzed. MS/MS was 
performed in the LTQ using data dependent dynamic 
exclusion of the top 20 most intense peptides using 
repeat count =  1, repeat duration =  30  s, exclusion list 
size of 500 and exclusion list duration = 30 s as a param-
eters. The top 20 most intense peptides were isolated and 
fragmented by low energy CID, 35% collision energy.
Database search and protein identification
Raw spectral data from Xcalibur™ (Thermo Scientific, 
v2.1) was searched against a custom database compiled 
from [27] in FASTA format for uploading it into Androm-
eda Search Engine 1.4. The database contained complete 
and partial sequences of PRRSV (22 976 sequences) and 
Sus scrofa (59 898 sequences). The sequence for trypsin 
from Sus scrofa (Accession P00761 from [28]) and default 
contaminant database were also included in the search 
carried out with Maxquant 1.5/Andromeda 1.4 software. 
Contaminants and proteins identified only by site modi-
fication were filtered out from the list. Proteins found in 
all groups were scored positive if they had at least two 
unique peptides and 1% False Discovery Rate (FDR) for 
protein and peptide identification. After filtering, pro-
teins of each group were compared in a Venn diagram 
using Venny 2.0 software [29] to determine which pro-
teins were unique and shared among samples.
Gene ontology (GO) analyses by PANTHER 
overrepresentation test
Porcine proteins identified by Maxquant 1.5/Andromeda 
1.4 Software were filtered by elimination of “contami-
nants” and “Only identified by site proteins”. Then, the 
most common proteins with highest score were sum-
mited to UniprotKb “retrieve/ ID mapping [28] to convert 
GI numbers (Maxquant results) to UniprotKB ID num-
ber and eliminating redundant hits. Then, the final pro-
tein list (184) (.tab format) was summited to PANTHER 
Overrepresentation Test (release 20150430) [30] using 
Annotation Version: PANTHER version 10.0 Released 
2015-05-15, Reference List: Sus scrofa (all genes in data-
base) and perform all three GO-Slim analysis available 
(Biological process, Cellular component and Molecular 
function) [31]. Also, exosomal proteins of Sus scrofa were 
compared against exosome proteins of different farm ani-
mals (Bos taurus, Equus caballus, Gallus gallus and Rat-
tus norvegicus) using Funrich analysis software [32].
ELISA assays
An indirect ELISA protocol was initially performed 
(dilution chessboard) for titration of sera coming from 
NV, V and CN pigs using a secondary antibody Goat 
anti-Pig IgG (Fc): HRP (AbSerotec AAI41P) and Por-
cillis PRRSV vaccine as coating antigen (Intervet Lot. 
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A200ED03) (Additional file  2). Using a range of sera 
dilutions previously titrated, circulating IgG antibodies 
from NV and CN pigs were tested in a double ELISA test 
against homologous NV serum-derived exosomes (sand-
wich ELISA) and against whole viral vaccine (Porcillis 
PRRS Vaccine “intervet” lot. A200ED03) as previously 
described. For sandwich ELISAs, plates were first coated 
with anti-CD63 antibodies and after washing and block-
ing, SEC fractions (100 uL per well) containing exosomes 
were incubated 90 min at 37 °C. Sera samples were after-
wards incubated for 1  h at room temperature, washed 
and incubated with secondary antibody Goat anti-Pig 
IgG (Fc): HRP (AbSerotec AAI41P) at 1:10  000 dilution 
and optical density was measured at 450 nm using Vari-
oskan equipment (Thermo Scientific).
Scaling‑up process for vesicle enrichment and isolation
The process of polyethylene-glycol (PEG) precipitation 
was based on scale-up process for retrovirus stock in 
order to maintain structure and functionality of extra-
cellular vesicles [33, 34]. Thus, two adult healthy ani-
mals (80–100  kg) were anesthetized and approximately 
500 mLs of peripheral blood from each animal collected 
by venous puncture. Blood was collected into 50 mL Fal-
con tubes to facilitate collection of sera and minimize 
hemolysis. Sera were precipitated overnight at room tem-
perature by adding PEG at 8.5% w/v ratio. Pellets were 
resuspended in 20 mLs of PBS and loaded into PuriFlash 
Dry Load Columns 80G (Interchim) filled with 100 mL of 
sepharose CL-2B (separation matrix) and 5 mLs fractions 
collected for further analysis.
Results
Characterization of serum‑derived exosomes 
after purification by size exclusion chromatography
SEC was used to isolate exosomes from sera of naïve ani-
mals (CN) pertaining to a PRRSV negative farm, and sera 
from viremic animals (V) or non-viremic (NV) animals 
from two PRRSV positive farms where different PRRS 
viruses were detected. Preliminary studies on sequence 
polymorphisms from PRRSV viruses isolated in these 
farms revealed 85% homology among them (data not 
shown). Twenty 0.5 mL aliquot fractions were collected 
from each serum and individually analysed for (i) for their 
protein content and (ii) for the presence of two “classical” 
exosome markers, CD63 and CD81. In all samples ana-
lysed, exosome markers were identified in fractions 7–10, 
whereas total protein content increased in later fractions 
(Figure 1A). In addition, NTA revealed that preparations 
from all animals were highly homogeneous in terms of 
particle size (100–200 nm with a medium size of 127 nm) 
and concentration (109–1010 particles per mL) (Figure 1B; 
Additional file  3). Furthermore, electrophoresis of the 
protein content of SEC fractions from different sam-
ples revealed a similar profile in early fractions and, as 
expected, an enrichment of plasma proteins in late frac-
tions (Figure  1C). Vesicle size and structure were also 
analysed by cryo-TEM. Similar to NTA, vesicles from 
80–200  nm in diameter were predominantly observed 
whereas electro-dense bodies typically associated with 
viral particles, were not (Figure 1D).
Proteomic analysis
To characterize the exosome protein composition from 
different groups of animals, liquid chromatography and 
mass spectrometry were applied for protein sequencing 
and identification from samples of one NV animal and 
two V animals (Figure  2). Of importance, peptides per-
taining to viral proteins were identified in serum-derived 
exosomes from all animals whereas others were uniquely 
identified. Thus, peptides from major envelope glyco-
protein GP5-Tm:pFc (a fusion protein of GP5 with no 
transmembrane domain and pig fragment crystallizable 
portion), from envelope glycoprotein GP3, NSP2 and 
partial ORF2b were detected in exosomes from all (NV 
and V) animals. Other peptides from nucleocapsid pro-
tein, envelope glycoprotein GP3 protein, major envelope 
glycoprotein GP5 and replicase polyprotein 1ab, where 
only identified in exosomes from V animals whereas 
peptides from envelope glycoprotein 3 were identified in 
exosomes from one V and one NV animal. Interestingly, 
peptides from RNA-dependent RNA polymerase and 
nucleocapsid protein N, were detected only in exosomes 
from NV animals.
To confirm the presence of unique viral proteins in 
exosomes from NV animals, three additional samples 
were also analysed by liquid chromatography and mass 
spectrometry and confirmed the presence of RNA-
dependent RNA polymerase, partial and nucleocapsid 
protein N. None of these proteins were found in serum-
derived exosomes from naïve animals (CN) further con-
firming the specificity of these results (not shown).
The proteomics analysis also identified more than 
400 porcine proteins contained within exosomes (Addi-
tional file 4). Of interest, GO analysis showed an impor-
tant enrichment of lipid transport, response to external 
stimulus, proteolysis, enzymatic activities and extracel-
lular space proteins, all related to exosomes composition 
and function (Table  1). Besides, when comparing exo-
some porcine proteins in our database with exosomes 
from other farm animals using the Funrich software [32], 
48 proteins were shared among B. taurus and S. scrofa 
(approximately 2.9% of total proteins), 5 with E. caballus, 
6 with G. gallus and 3 with R. norvegicus as outlier in the 
evolutionary line (Additional file  5). Interestingly, even 
though the pig protein database is smaller than others in 
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Figure 1 Characterization of porcine serum-derived exosomes sera by different methodologies. Bradford and flow cytometry analyses 
(A), nanoparticle tracking analysis (B), cryo‑electron microscopy (C) and SDS‑PAGE/Silver Staining (D) are represented. MFI: Median fluorescence 
unit, mg/mL: Bradford measure unit, M: Molecular weight marker, F6‑F9: Fraction number from SEC and percentage (%) size distribution (nm).
Figure 2 Venn diagram showing overlap and unique peptides of viral proteins detected in different sample groups: non-viremic 
(201406-6PS) and viremic (201406-2PS and 201406-4PS). The overlapping and unique peptides identified for proteins in these sample 
groups are shown.
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these analyses, there is a coincidence of 3% with Bos tau-
rus, and at least 4 of these proteins are classical exosomal 
markers (CD5, CD9, CD81 and CD63) (Additional file 5).
Specific immune recognition of PRRSV‑proteins 
in serum‑derived exosomes
To determine whether serum-derived exosomes from 
NV animals contained antigenic viral proteins, swine 
sera was tested by indirect and sandwich ELISA. First, 
sera was titrated using Porcilis PRRSV vaccine as coating 
antigen and showed maximum differences between CN 
and NV animals at 1/50–1/100 dilutions and 1/10  000 
dilution of the secondary antibody without being at satu-
ration values (Additional file  2). As shown in Figure  3, 
statistically significant differences (p  <  0.05) between 
sera from NV and CN animals using three individual 
NV exosome preparations (1PS, 2PS and 3PS) at 1/50 
and 1/100 dilutions, were observed. Moreover, simi-
lar reactivity and statistical significance were observed 
when sera from CN and NV animals were tested against 
a commercially available vaccine (Porcillis PRRSV vac-
cine, Intervet) as the coating antigen. In addition, 
evaluation of antigenicity was done in concentrated 
exosome samples obtained through PEG/SEC isolation. 
Non-viremic sera but not naïve was able to recognize 
exosomes derived from non-viremic animals in a dose 
dependent manner (Figure 4).
Scaling‑up process for vesicle enrichment and isolation
Approximately half litre of peripheral blood was obtained 
from each of two anesthetized animals and their sera col-
lected following standard procedures. Sera were precipi-
tated using PEG, pellets suspended into 20  mL aliquots 
and passed through individual Sepharose CL-2B 100 mL 
columns. Results demonstrated that this escalation pro-
cedure yielded purified exosomes with the same NTA 
profile, SDS-PAGE and cryo-EM as those obtained from 
2  mL aliquots of serum (Figure  4). Noticeably, the yield 
was significantly increased as proteins were detected by 
the Bradford assay in SEC fractions containing exosomes 
(Figure 4A) and NTA analysis revealed a twofold increase 
in the number of particles (1010–11 particles/mL) as 
opposed to those obtained from 2 mLs (108–9 particles/
mL). Last, PEG-precipitation did not affect the immuno-
logical properties of exosomes as immune sera similarly 
and specifically recognized them (Figure 4B).
Table 1 Gene Onthology analysis of Sus scrofa proteins detected in exosomal enriched fractions
Ref list. 21483 Exp. list (91) Expected Over/under Fold enrichment P value
PANTHER GO‑slim biological process
 Lipid transport 305 10 1.29 +  >5 1.67E−04
 Response to external stimulus 347 10 1.47 +  >5 5.24E−04
 Proteolysis 690 12 2.92 + 4.11 7.98E−03
 Response to stress 659 11 2.79 + 3.94 2.48E−02
 Immune system process 1399 17 5.93 + 2.87 1.65E−02
 Localization 2610 28 11.06 + 2.53 4.69E−04
 Transport 2484 26 10.52 + 2.47 1.93E−03
 Response to stimulus 2364 23 10.01 + 2.3 2.31E−02
 Unclassified 9376 24 39.72 − 0.6 0.00E+00
PANTHER GO‑slim molecular function
 Lipid transporter activity 106 8 0.45 + >5 3.51E−06
 Peptidase inhibitor activity 227 10 0.96 + >5 8.65E−06
 Serine‑type peptidase activity 293 11 1.24 + >5 8.91E−06
 Enzyme inhibitor activity 337 10 1.43 + >5 3.08E−04
 Peptidase activity 605 16 2.56 + >5 9.26E−07
 Receptor binding 947 18 4.01 + 4.49 1.42E−05
 Hydrolase activity 2181 23 9.24 + 2.49 5.06E−03
 Protein binding 2729 28 11.56 + 2.42 8.53E−04
 Unclassified 10 794 35 45.72 − 0.77 0.00E+00
PANTHER GO‑slim cellular component
 Extracellular space 6 3 0.03 + >5 1.22E−04
 Extracellular region 624 18 2.64 + >5 6.31E−09
 Unclassified 17 295 62 73.26 − 0.85 0.00E+00
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Discussion
Here, for what we believe is the first time, we describe the 
isolation, characterization, antigenicity and scaling-up 
process of serum-derived exosomes from naïve pigs and 
from pigs actively or previously infected with PRRSV.
Firstly, size-exclusion chromatography was applied to 
analyze serum-derived exosomes from pigs in a small and 
scaling-up procedure. This single-standing methodology 
is presently considered a solid and reproducible method 
for isolation and characterization of extracellular vesicles 
in the size range of exosomes from different biological 
fluids such as plasma [25, 35], saliva [36] and urine [37]. 
In fact, it removes most contaminant abundant proteins 
and purifies 100–200  nm particles associated with clas-
sical exosomal markers. Accordingly, our results showed 
that exosomes eluted in fractions 7 to 10, whereas more 
abundant serum proteins (such as albumin), as judged by 
the Bradford assay, eluted in later fractions. Moreover, 
two “classical” exosomal markers, CD63 and CD81 [38] 
showed maximum MFI values in these same fractions 
(Figures  1, 4), where high concentrations of particles in 
the size-range of exosomes were also detected by NTA 
and cryo-TEM analyses and low protein content was 
detected. Of interest, bicosome-like structures (vesicles 
within vesicles) were observed in agreement with simi-
lar structures found in structural studies from other flu-
ids [39–41]. These results strongly suggest that porcine 
serum samples have similar and reproducible SEC elu-
tion profiles as described in human samples, reinforcing 
the use of SEC as a single-standing and easily implement-
ing technology facilitating field studies of extracellular 
vesicles in animal diseases of veterinary importance.
To identify PRRSV viral proteins associated with 
serum-derived exosomes, we used nanoLC-MS/MS. 
Remarkably, RNA-dependent RNA polymerase, par-
tial and nucleocapsid protein N, were detected only in 
exosomes from the non-viremic animals (Figure 2). The 
nucleocapsid protein (N) is one of the most abundant 
and immunodominant viral proteins during PRRS infec-
tion [42]. This protein interacts with different cellular 
factors of the host to facilitate virus infection and its role 
is crucial for mature viral particle formation within the 
Figure 3 ELISA assay for evaluation of NV and CN porcine sera immune recognition over inactivated viral particle PRRSV vaccine 
(Porcilis PRRS, Intervet) and exosomes derived from NV porcine sera of different origin. Analyses of naïve (CN) and non‑viremic (NV) sera 
against exosomes derived from sample 201502‑1PS (A), 201502‑2PS (B) and 201502‑3PS (C). Optical density (OD) was measured at 450 nm and it is 
represented in the “Y” axis. “X” axis shows the dilution factor for sera samples (1/50 to 1/400). For each animal, exosomes were isolated and captured 
using anti‑CD63 antibody and tested against both sera (**p < 0.01; ***p < 0.0001).
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cell, binding to the viral RNA genome and replication 
machinery including RNA-dependent RNA polymerase, 
and also interacts with itself to form the core capsid [43, 
44]. Of interest, the N protein and three non-structural 
(Nsps) PRRSV proteins have been identified as playing 
an important role in type I IFN suppression and modu-
lation of the NF-kB pathway as it is translocated to the 
nucleus during early stages of infection [43, 45]. Late in 
infections, nucleocytoplasmic transport of the N pro-
tein increase the cytoplasmic concentration of this pro-
tein. It is tempting to speculate that an increase in virus 
N protein at cytoplasm during chronic infections might 
favor the release of the N-protein and RNA-dependent 
RNA polymerase in exosomes, which could at least par-
tially explain the data from the proteomic analysis. In 
the absence of supporting data, this remains to be fur-
ther demonstrated. Regardless, N proteins has been 
expressed in different models such as Baculovirus and 
Escherichia coli [42] and soya been seeds [46]; interest-
ingly, in all cases it was capable of inducing both cellular 
and humoral immune response (murine model) or being 
recognized by PRRSV immune porcine sera.
To test the antigenic properties of serum-derived 
exosomes from previously infected animals, we first cap-
tured exosomes isolated from three non-viremic (NV) 
animals that were free of detectable virus (RT-PCR nega-
tive) at the time of sera collection. Analysis of serum-
derived exosomes from V animals was not performed in 
sandwich ELISA as PRRSV virus has the same density 
and size of exosomes; thus, confounding such analyses. 
Immune sera from pigs previously exposed to PRRSV, 
specifically reacted to these exosomes in a dose-depend-
ent manner and similar, albeit at lower values, to anti-
gens contained in the Porcillis attenuated vaccine; these 
results thus demonstrate that viral proteins contained in 
the exosome preparation from NV animals are antigenic. 
The immunogenic properties of exosomes containing 
pathogen-associated antigens have been tested in sev-
eral preclinical models and diseases [18, 19, 47]. Yet, to 
the best of our knowledge, no reports are presently avail-
able on antigenic properties of serum-derived exosomes 
with no pathogen load detected in peripheral circulation. 
This observation may be of importance for future vaccine 
approaches.
As a bonafide aspect of these analyses, we present 
the first proteomics analysis of pig proteins contained 
in serum-derived exosomes (Additional file  2). More 
than 400 porcine proteins associated with lipid trans-
port, response to external stimulus, response to stress, 
immune system processes, some enzymes and extracellu-
lar space proteins are enriched in our exosomal fractions 
indicating cargo-selection related to cell communica-
tion and metabolic processes. These proteins thus repre-
sent a first baseline proteome of porcine serum-derived 
exosomes facilitating future studies between host and 
pathogens in PRRSV and other animal diseases.
The use of nanovesicles in vaccine approaches against 
PRRSV is bringing new and recent exciting data. It has 
been previously reported that nanoparticle entrapped 
antigens are more effective than conventional vaccine 
Figure 4 Characterization of exosomes isolated using PEG/SEC methodology from porcine sera. Bradford and flow cytometry analyses 
(A), Sandwich ELISA for exosomes derived from non‑viremic animal (B), are represented. MFI: Median fluorescence unit, mg/mL: Bradford measure 
unit, CD63‑CD81 are molecular markers for exosomes characterization. For FACS and Bradford analyses is evident that higher values are represented 
in comparison with non‑concentrated samples (10‑fold change). In addition, the indirect quantification through Bradford of protein associated with 
exosomes it is possible when sera is concentrated through PEG and separated using SEC, making this an important tool for further evaluation of 
immunogenic properties in vitro and in vivo. For the sandwich ELISA, exosomes derived from non‑infected animal were tested against two types of 
porcine sera. Optical density (OD) was measured at 450 nm and represented in the “Y” axis. “X” axis shows the dilution factor for exosomes samples 
(1 to 1/200). Duplicated values are represented as squares and dots and mean as a line.
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platforms [48–50] and demonstrated increasing titers of 
virus neutralizing antibodies in serum and lungs. Addi-
tionally, a different kind of artificial exosome was used 
to deliver microRNA into porcine alveolar macrophages 
(PAMs) to suppress expression of CD163 or Sialoadhesin 
receptors in cell surface making those less susceptible 
to PRRSV infection and replication [51]. Our results, 
including a scaling-up process, thus warrant further 
exploring serum-derived exosomes from PRRSV infec-
tions as a different vaccination approach. Regulatory 
aspects, similar to what has been recently positioned 
by the International Society of Extracellular Vesicles on 
human health [52], should not encounter major obstacles 
in future animal trials.
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Additional file 2. ELISA chessboard plate assay for standardization 
of NV, CN and V porcine sera immune recognition over inactivated 
viral particle PRRSV vaccine (Porcilis PRRS, Intervet). Analyses 
of different dilutions of secondary antibody (A) 1/100, (B) 1/1000 (C) 
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dilution factor for sera samples (1/5 to 1/5000) and each bar represents a 
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further experiments was selected by comparison of differences between 
non‑viremic and naïve samples and selecting the ones showing highest 
difference combined with highest dilution without signal saturation (1/50 
for sera and 1/10 000 for secondary antibody).
Additional file 3. Naïve and viremic protein, FACS and nanosight 
profile. (A) (C) Viremic sample 201406-2PS (B) (D) Naïve sample 
201406-CN2. Viremic and naïve samples of sera were evaluated by the 
same methodology as non‑viremic samples to detect any differences 
between groups. Protein and molecular markers profile were similar as 
already seen with non‑viremic samples, where fractions enriched with 
exosomes exhibit higher MFI values for CD63 and CD81 even though 
there is no measurable protein detected by Bradford assay.
Additional file 4. Sus scrofa proteins identified by Maxquant/
Andromeda analysis using nanoLC-MS/MS spectra. Porcine proteins 
were identified in exosomes by proteomic analyses and several molecular 
markers of exosomes are present in these samples such as CD5, CD9, 
CD81 and CD63.
Additional file 5. Venn diagram of farm animal exosomal proteins 
and coincidence table comparing Sus scrofa and Bos taurus. 
Exosome proteins from different farm animal species obtained from 
Vesiclepedia were used to compare with our Sus scrofa exosomal proteins. 
Similarities among species in exosomal proteins are represented in the 
venn diagram.
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